NICE backs Veklury for treatment of COVID-19 in high-risk patients

UK health technology assessor the National Institute of
Health and Care Excellence (NICE) has published final draft
guidance recommending use of remdesivir for treating COVID-19 in
eligible adults and children.

Marketed by US antivirals giant Gilead Sciences (Nasdaq: GILD)
under the trade name Veklury, remdesivir was the first medicine
for COVID-19 to receive full marketing authorization in 2022.
However, as the pandemic receded, sales of the…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.